← Pharmacy curriculum
Module 12610 lessonsRxPrep 2023 Chapter 39, 2023 American Academy of Dermatology and AAAAI/ACAAI topical therapy guidelines, current DailyMed hydrocortisone, clobetasol, triamcinolone, and fluticasone labeling, and peer-reviewed fingertip-unit evidence

Topical Corticosteroid Pharmacology and Safe Use

Connect glucocorticoid pharmacology to product potency, vehicle, site, quantity, schedule, local toxicity, systemic absorption, special populations, monitoring, and steroid-sparing care.

01

Explain glucocorticoid receptor signaling, inflammatory transcription control, and the limits of symptomatic suppression.

02

Verify potency as a formulation-specific property and distinguish low-potency OTC therapy from super-high-potency prescription products.

03

Choose a vehicle and potency from lesion, site, skin thickness, hair, barrier, diagnosis, patient preference, and product labeling.

04

Calculate fingertip units and course quantities from treated area, frequency, duration, and package constraints.

05

Prevent local atrophy, infection masking, ocular exposure, HPA-axis suppression, and cumulative corticosteroid toxicity.

06

Adapt treatment for children, older adults, pregnancy, lactation, fragile skin, recurrent disease, and steroid-sparing plans.

126.01

Lesson

Move From Skin Delivery to Gene Regulation

A topical corticosteroid must reach viable skin, cross cell membranes, bind the glucocorticoid receptor, and change inflammatory transcription. The same mechanism that controls disease can suppress repair and host defense.

What to learn
  • Glucocorticoid receptor
  • Transcription
  • Cytokines
  • Eicosanoids
  • Vasoconstriction
Cellular controlA glucocorticoid crosses the membrane, binds its receptor, changes transcription, and quiets inflammatory signaling
01EnterLipophilic drug crosses skin and cell membranes

Vehicle and barrier determine delivery

02BindCytosolic glucocorticoid receptor

The complex changes location and activity

03RegulateInflammatory gene transcription

Cytokines and eicosanoid signaling decline

04ResolveErythema, edema, and pruritus improve

Diagnosis still determines whether suppression is appropriate

Reach the target tissue

Percutaneous delivery begins at the stratum corneum. Vehicle, hydration, barrier integrity, inflammation, body site, area, and occlusion determine how much drug reaches living tissue.

Activate the receptor

Lipophilic corticosteroid enters the cell and binds a cytosolic glucocorticoid receptor. The activated complex changes nuclear transcription and interacts with inflammatory signaling networks.

Reduce inflammatory output

Glucocorticoid signaling induces anti-inflammatory proteins and reduces phospholipase, eicosanoid, cytokine, immune-cell, and vascular activity.

Respect mechanism limits

Suppression is not diagnosis. Tinea, bacterial infection, herpes, acne, rosacea, and perioral dermatitis can temporarily look quieter while the underlying process persists or worsens.

Quick check

0 of 1 answered
01What is the central intracellular target of topical corticosteroids?
Answer every question to submit.
126.02

Lesson

Treat Potency as a Product Property

Topical corticosteroids span low through super-high potency. Molecule, salt or ester, concentration, vehicle, assay, and exact formulation determine class, so ingredient names cannot be ranked in isolation.

What to learn
  • Seven groups
  • Concentration
  • Vehicle
  • Hydrocortisone
  • Clobetasol
Potency is a formulation propertyMolecule, concentration, vehicle, assay, and product determine class, so a drug name alone is insufficient
01LowHydrocortisone examples

Useful where safety margin is narrow

02MiddleMany prescription formulations

Match disease, site, and duration

03HighThick plaques and resistant sites

Risk rises with area and exposure

04Super-highClobetasol examples

Strict label limits and monitoring apply

Read beyond the ingredient

Different concentrations and vehicles of one corticosteroid can occupy different potency groups. Confirm the active ingredient, concentration, dosage form, and label rather than relying on memory.

Use low potency deliberately

OTC hydrocortisone 0.5 to 1 percent provides temporary relief for selected mild inflammatory rashes. Thin skin and self-care do not remove the need for site and duration limits.

Reserve high potency for a reason

Thick plaques and resistant sites may require higher potency, but large area, prolonged use, occlusion, children, fragile skin, and impaired barrier increase toxicity.

Anchor super-high potency to the label

One current clobetasol emollient cream label limits responsive dermatosis treatment to two consecutive weeks and total use to 50 grams per week. Other products and indications can differ.

Quick check

0 of 1 answered
01What information is required to determine topical corticosteroid potency?
Answer every question to submit.
126.03

Lesson

Choose the Vehicle as Part of the Dose

Ointments, creams, lotions, solutions, gels, foams, oils, sprays, shampoos, and tapes change hydration, spread, evaporation, occlusion, tolerability, and adherence.

What to learn
  • Ointment
  • Cream
  • Solution
  • Foam
  • Occlusion
Delivery architectureThe same active ingredient can behave differently when the vehicle changes hydration, evaporation, spread, and occlusion
01OintmentGreasy and occlusive

Often useful for dry thick lesions

02CreamBalanced and acceptable

Preservatives can matter

03SolutionLow residue on hair-bearing skin

Alcohol can sting disrupted skin

04Foam or gelRapid spread and drying

Flammability and product directions matter

Use ointment for occlusive delivery

Ointments have little water, reduce transepidermal water loss, and often suit dry thick nonhairy lesions. Greasiness and follicular occlusion can reduce acceptance.

Use cream for flexible spread

Creams are less greasy and often easier to use in folds or during the day, but preservatives, emulsifiers, and other inactive ingredients can irritate or sensitize.

Reach hair-bearing skin

Solutions, foams, gels, oils, sprays, and shampoos can improve scalp and hair-bearing delivery. Alcohol can sting disrupted skin, and aerosol or foam products may be flammable.

Treat occlusion as a dose multiplier

Wraps, diapers, skin folds, and tape increase hydration and absorption. Occlusive therapy is clinician-directed because local and systemic exposure can rise sharply.

Quick check

0 of 1 answered
01Which vehicle often suits a dry thick nonhairy plaque?
Answer every question to submit.
126.04

Lesson

Match Potency to Anatomy and Diagnostic Certainty

Eyelids, face, folds, groin, and genitals absorb more and develop atrophy more readily. Palms, soles, and lichenified plaques resist penetration. Hair and infection add another axis.

What to learn
  • Thin skin
  • Thick skin
  • Folds
  • Hair
  • Infection
Site-risk matrixThin skin, folds, thick plaques, hair, infection, and diagnostic uncertainty change the formulation and potency decision
01ThinFace, eyelids, folds, genitals

Use a larger safety margin

02ThickPalms, soles, lichenified plaques

Delivery can be difficult

03HairScalp and dense hair

Solution, foam, oil, or shampoo may improve reach

04UncertainTinea, rosacea, acne, infection

Confirm before suppressing inflammation

Protect thin and critical skin

Use a larger safety margin around eyelids, face, intertriginous folds, groin, and genitals. Ocular proximity and functional consequence often justify clinician review or a nonsteroid alternative.

Reach thick resistant skin

Palms, soles, and lichenified plaques can require a stronger formulation or different vehicle, but the plan still defines area, duration, and exit strategy.

Do not suppress an uncertain diagnosis

Annular scale, active borders, pustules, crust, pain, vesicles, burrows, dermatomal distribution, or treatment failure can signal infection or another mimic.

Prevent tinea incognito

Corticosteroids can reduce redness while a dermatophyte infection expands with altered morphology. Temporary cosmetic improvement is not proof of correct treatment.

Quick check

0 of 1 answered
01Why should a potent body corticosteroid not automatically be used on an eyelid?
Answer every question to submit.
126.05

Lesson

Convert Apply Thinly Into a Reproducible Quantity

The fingertip unit translates a semisolid column into treated area and course quantity. It prevents both vague underdosing and uncontrolled excess.

What to learn
  • Standard nozzle
  • One-half gram
  • Two percent body area
  • Course quantity
  • Adherence
Quantity translationThe fingertip unit converts vague instructions into an amount tied to body area
01MeasureTip to distal finger crease

Assumes a standard nozzle

02MassAbout one-half gram

An approximation, not a universal package constant

03CoverageAbout two percent adult body area

Roughly two adult handprints

04CourseArea times frequency times days

Prescribe enough without uncontrolled excess

Define one unit

One adult fingertip unit is the amount expressed from the distal crease to the tip of the index finger through a standard nozzle.

Use the coverage estimate

One fingertip unit is approximately one-half gram and covers about two percent of adult body surface area, roughly two adult handprints.

Calculate the full course

Multiply units per application by applications per day and treatment days. Multiply by about one-half gram per unit when a gram estimate is required.

Teach the approximation

Nozzle diameter, formulation, hand, waste, and technique introduce variation. Demonstration and follow-up are more useful than pretending the estimate is exact.

Quick check

0 of 1 answered
01Approximately how much product is 14 adult fingertip units?
Answer every question to submit.
126.06

Lesson

Build the Exit Into the Starting Plan

Application frequency and duration follow the exact product, disease, site, response, and maintenance strategy. Once- or twice-daily use is common, but there is no universal schedule based only on potency.

What to learn
  • Frequency
  • Control target
  • Step-down
  • Maintenance
  • Treatment failure
Course designDiagnosis, label, potency, response, duration, and maintenance plan define the schedule
01StartApply to active disease as directed

Do not substitute more frequent use for reassessment

02ReviewTrack control and toxicity

Stop or step down when the goal is reached

03MaintainProactive intermittent therapy when prescribed

Not every disease needs continuous daily steroid

04EscalateFailure, infection, or uncertainty

Recheck the diagnosis before increasing exposure

Follow product and disease directions

Do not convert the broad idea that some potent products work once daily into a universal rule. Read the label and the disease-specific treatment plan.

Apply to the intended field

Use the prescribed quantity on active disease or a specifically designated maintenance site. Wash hands afterward unless the hands are being treated.

Stop or step down when controlled

Continuing the initial potency indefinitely increases exposure without proving additional benefit. Move to barrier care, lower intensity, or prescribed intermittent maintenance.

Investigate failure before escalation

Check diagnosis, quantity, frequency, vehicle, adherence, contact allergy, infection, trigger persistence, package confusion, and access before increasing potency.

Quick check

0 of 1 answered
01What is the best response to apparent treatment failure?
Answer every question to submit.
126.07

Lesson

Recognize the Skin Pattern of Excess Exposure

Local toxicity includes atrophy, striae, telangiectasia, purpura, pigment change, acneiform eruption, rosacea, perioral dermatitis, infection masking, delayed healing, and contact allergy.

What to learn
  • Atrophy
  • Striae
  • Telangiectasia
  • Infection masking
  • Contact allergy
Local toxicity mapPotency, duration, site, occlusion, and barrier damage determine the pattern of cutaneous injury
01StructureAtrophy, striae, telangiectasia, purpura

Thin skin is more vulnerable

02InflammationAcneiform, rosacea, perioral dermatitis

Steroid suppression can reshape disease

03DefenseMasked or worsened infection

Tinea incognito is a diagnostic warning

04RepairDelayed healing and pigment change

Follow the tissue trajectory

Inspect structure

Compare treated and untreated skin for thinning, transparency, striae, visible vessels, bruising, tearing, and loss of elasticity.

Recognize treatment-induced eruptions

Facial papules, pustules, rosacea-like change, perioral dermatitis, and acneiform lesions can be caused or perpetuated by corticosteroids.

Find concealed infection

Fungal borders can flatten, bacterial infection can spread, and viral lesions can worsen when inflammatory signals are suppressed.

Consider product allergy and repair

Worsening, burning, delayed closure, or a new geometric border can reflect allergy to the active drug or vehicle, irritant exposure, or impaired healing.

Quick check

0 of 1 answered
01Which finding most strongly suggests local corticosteroid toxicity?
Answer every question to submit.
126.08

Lesson

Stack Every Factor That Raises Systemic Exposure

Topical therapy can suppress the HPA axis. Risk accumulates with potency, grams, area, duration, occlusion, barrier disruption, multiple steroid products, childhood, and impaired clearance.

What to learn
  • HPA axis
  • Cushing features
  • Hyperglycemia
  • Occlusion
  • Cumulative exposure
HPA risk stackPotency, area, duration, occlusion, barrier loss, multiple products, age, and organ reserve accumulate
01EntryInflamed or disrupted barrier

Percutaneous absorption increases

02DoseLarge area or high potency

Total weekly grams matter

03AmplifyOcclusion and prolonged use

Hydration increases penetration

04EffectHPA suppression, Cushing features, hyperglycemia

Withdrawal can expose adrenal insufficiency

Map the risk stack

Higher potency, large surface area, prolonged use, occlusion, inflamed or damaged barrier, multiple products, and liver dysfunction increase systemic absorption.

Recognize endocrine effects

Reversible HPA-axis suppression, Cushing features, hyperglycemia, glucosuria, and impaired growth can occur. Withdrawal after substantial exposure can reveal glucocorticoid insufficiency.

Use label limits precisely

A current clobetasol emollient cream label limits total use to 50 grams per week and usually limits responsive dermatosis treatment to two weeks. Do not generalize one label to every formulation.

Monitor proportionately

High-risk patients may require clinician-directed cortisol assessment or ACTH stimulation testing. Low-risk short courses do not need indiscriminate laboratory screening.

Quick check

0 of 1 answered
01Which combination creates the greatest HPA-axis risk?
Answer every question to submit.
126.09

Lesson

Adjust for Surface Area, Reserve, and Contact

Children have more skin area relative to body mass. Older adults may have fragile atrophic skin. Pregnancy and lactation require product-specific exposure and infant-contact planning.

What to learn
  • Children
  • Diaper occlusion
  • Older adults
  • Pregnancy
  • Lactation
Reserve and exposureChildren, older adults, pregnancy, lactation, and fragile skin require product-specific selection rather than one universal rule
01ChildrenHigher surface area relative to mass

Systemic exposure can rise

02Older skinAtrophy and purpura risk

Use a deliberate site and duration plan

03PregnancySmallest effective exposure

Use current product evidence, not retired letters

04LactationPrevent infant contact and ingestion

Nipple use requires a feeding plan

Adapt without abandoning protectionAge, pigment, sensitivity, pregnancy, lactation, and heat change the plan
01InfantShade and clothing first

Prevent overheating

02PigmentTint and iron oxides

Visible-light protection can matter

03SensitiveTolerated formulation

Vehicle and ingredients differ

04ReproductiveProduct-specific assessment

Retired letters do not decide care

Adapt the planAge, skin tone, hair texture, pregnancy, lactation, immune status, and neurologic disease alter assessment and delivery
01InfantCradle cap

Gentle scale care, no adult shampoo assumption

02HairCoils and protective styles

Build a feasible scalp schedule

03Skin toneErythema may look different

Track pigment change and texture

04HostImmune or neurologic risk

Lower the threshold for evaluation

Change the safety marginAge, prematurity, diarrhea, antibiotics, immune status, mobility, and incontinence alter exposure and risk
01NewbornThin immature barrier

Lower threshold for clinical review

02DiarrheaFrequent enzyme-rich stool

Change and protect more often

03AntibioticCandida risk rises

Use morphology, not prophylactic antifungal

04Older child or adultIncontinence-associated dermatitis

Pressure and wound care may coexist

Individual safetyCoordinate household care without erasing drug-specific differences
01ChildExact age and weight

Evidence and labeling differ below age two

02PregnancyCurrent risk-benefit review

Retired letter categories are not used

03LactationDrug-specific evidence

Mebendazole data differ from other options

04ComorbidityLiver, allergy, swallowing

Select product and plan individually

Protect children from disproportionate exposure

Children can absorb a larger dose relative to body mass. Verify age labeling, treated percent body area, duration, caregiver quantity, growth, and unintentional diaper occlusion.

Protect fragile older skin

Baseline atrophy, purpura, anticoagulants, falls, wound risk, and caregiver application can magnify structural complications.

Replace pregnancy letters with exposure reasoning

Review the exact product, potency, area, duration, trimester, disease burden, alternatives, and current pregnancy evidence. Retired letter categories do not answer the question.

Prevent infant contact during lactation

Use product-specific lactation guidance. Avoid infant skin or oral contact with treated areas, and coordinate any breast or nipple application with feeding and cleansing instructions.

Quick check

0 of 1 answered
01Why are children at greater risk of systemic topical corticosteroid exposure?
Answer every question to submit.
126.10

Lesson

Measure Control and Total Exposure Together

Monitoring connects disease severity, treated area, grams, duration, site toxicity, adherence, infection, and quality of life. Barrier care and indicated nonsteroid agents can reduce recurrent steroid burden.

What to learn
  • Treatment target
  • Exposure ledger
  • Barrier care
  • Steroid sparing
  • Follow-up
Control without driftDefine the target, measure exposure, protect the barrier, and add nonsteroid options when repeated control is needed
01TargetSeverity, itch, sleep, function

Know what success means

02ExposurePotency, grams, area, days, occlusion

Reconcile every product

03BarrierMoisturizer and trigger control

Foundational care lowers treatment burden

04AlternativeTCI, PDE4, JAK, or disease-specific therapy

Choose by indication, age, site, and safety

Define meaningful response

Track lesion area, thickness, scale, itch, sleep, pain, function, flare frequency, and patient goals rather than color alone.

Keep an exposure ledger

Record product, potency, grams, site, percent body area, frequency, days, occlusion, refills, and all inhaled, nasal, oral, injected, and combination steroids.

Build foundational care

Moisturizers, gentle cleansing, trigger control, infection management, and adherence support can lower anti-inflammatory demand in barrier diseases.

Use steroid-sparing therapy by indication

Topical calcineurin inhibitors, PDE4 inhibitors, JAK inhibitors, aryl hydrocarbon receptor agonists, phototherapy, and systemic options have disease-, age-, site-, and safety-specific roles.

Quick check

0 of 1 answered
01What is the most complete monitoring approach?
Answer every question to submit.

Module test

Check the connections.

Each attempt draws 10 questions from the complete 116 question bank.

116 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

References

Current clinical foundation.

Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.

  1. AAD Adult Atopic Dermatitis Topical Therapy Guideline
  2. AAAAI and ACAAI 2023 Atopic Dermatitis Guideline
  3. DailyMed Hydrocortisone 1 Percent Label
  4. DailyMed Clobetasol Emollient Cream Label
  5. DailyMed Triamcinolone Cream Label
  6. DailyMed Fluticasone Ointment Label
  7. Topical Corticosteroid Choice and Application Review
  8. Fingertip Unit Evidence
PharmacyOpen tools